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Alcohol consumption is responsible for one in every twenty deaths in the world, 
or 5.9% of all deaths globally1, and is the third leading cause of preventable death in the 
United States.2 There are over two hundred disease and injury states in which alcohol is 
considered to be an attributable factor in varying degrees. The alcohol-attributable 
factor is the degree to which the disease or injury can be attributed to alcohol use. With 
the exception of alcohol use disorders and fetal alcohol syndrome, alcoholic liver 
disease has the highest alcohol-attributable fraction of any alcohol related disease or 
injury state.1 
Alcoholic liver disease (ALD) accounts for almost one-fifth of all alcohol related 
deaths worldwide.1 In the United States, the death rate from cirrhosis (the end stage of 
ALD), drastically declined after the introduction of Prohibition in 1920 and then steadily 
increased until mid-1970.3 Death rates once again began to decrease at this time; 
participation in Alcoholics Anonymous and advances in treatment for substance abuse 
are believed to have driven this steady decline until the early 2000s, when this trend 
reversed.3 The age-adjusted death rate from liver cirrhosis due to alcohol use now 
appears to be on the rise again, with the death rate increasing by 18.6% from 2000 to 
2013.3,4 Potential factors contributing to recent increases in alcohol related cirrhosis 
deaths include declining trends in alcohol price and some states repealing laws 
prohibiting Sunday sales of alcoholic beverages, both factors associated with increased 
alcohol sales and per capita alcohol consumption.5, 6 
Liver cirrhosis can develop from several etiologies including nonalcoholic fatty 
liver disease, chronic viral hepatitis B and C, autoimmune primary biliary cirrhosis and 
excessive alcohol use.7 In the United States, liver cirrhosis was the twelfth leading 
cause of death in 2012, with 47.9% of all cirrhosis deaths related to excessive alcohol 
use.4 A recent study conducted by Shah et al examined disparities in referral of patients 
with liver disease to gastrointestinal and liver centers.8 ‘Early liver disease’ was defined 
as having no evidence of advanced fibrosis or cirrhosis, hepatocellular carcinoma or 
history of liver-related decompensations, while ‘advanced liver disease’ was 
characterized as decompensated cirrhosis, hepatocellular carcinoma or acute liver 
failure.8 This discernment between early and advanced liver disease is critical due to 
the irreversible nature of liver cirrhosis, therefore limiting possible interventions that may 
stop disease progression for individuals with advanced presentation of the disease.7 
The study analyzed 1,551 people with early liver disease and 1,597 people with 
advanced liver disease from sixteen gastrointestinal or liver centers across six different 







Figure 1. Etiologies of early and advanced liver disease  
 
Reproduced with permission from Shah et al 8 
 
For single etiologies of early liver disease, hepatitis C (HCV) accounted for 
31.2% of cases, hepatitis B (HBV) for 22.6% and nonalcoholic fatty liver disease 
(NAFLD) for 18.5%, while ALD accounted for only 2.8% of all patients with early liver 
disease. In comparison, people with ALD represented 31% of those with advanced liver 
disease and were 11.5 times more likely to present with advance disease than with 
early disease (p < 0.001). Also notable was for two etiologies of liver disease, alcohol 
was involved in 83.7% of cases. This group of two etiologies had the second highest 
prevalence of advanced liver disease, only behind ALD as a single etiology.8 
The findings from this study suggest a disparity in early referral in patients with 
ALD compared to patients with liver disease of other etiologies. These results 
demonstrate the need for directed efforts to increase early detection and referral of 
patients with ALD before decompensation occurs and intervention options decrease, to 
improve patient prognosis. This paper will explore some of the potential factors driving 
this disparity, as well as explore the unique role of the dietitian in attenuating disease 
severity to improve patient outcomes among those individuals with advanced stage 
ALD. 
 
Overview of the spectrum of alcoholic liver disease 
Pathogenesis of alcoholic liver disease 
Most people who regularly consume more than 40 grams of alcohol (about 2 - 3 
standard drinks) per day have some degree of liver steatosis.9 Liver steatosis occurs 
due to the synergistic effect of metabolic disturbances from heavy alcohol use and is 
characterized by the accumulation of fat in the liver cells.10 Steatosis typically does not 
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present with overt clinical symptoms however some people do experience abdominal 
pain or liver enlargement.11 Simple steatosis can be reversed with alcohol abstinence 
within several weeks.11, 12 Beyond steatosis, ALD manifests as a gamut of irregularities 
caused by varying levels of inflammation and/or development of fibrosis. Steatohepatitis 
is a condition that indicates inflammation is occurring concurrently with steatosis of the 
liver, and these physiological changes may lead to fibrosis and cirrhosis.12 It is also 
considered a reversible condition with alcohol abstinence, however any presence of 
fibrosis may persist in the liver.12 Steatohepatitis is determined by liver biopsy.12 
Alcohol hepatitis occurs when the liver experiences varying degrees of 
inflammation and injury, and presents with mild to severe symptoms including 
abdominal pain, jaundice, ascites, nausea, vomiting and fever.9 Patients presenting with 
alcohol hepatitis may be experiencing the first clinical representation of previously 
undiagnosed alcohol liver disease, or may be related complications associated with 
established and recognized liver cirrhosis.9 It was previously believed that alcoholic 
hepatitis could occur in individuals with mild or early stage liver disease, however recent 
studies consistently demonstrate that most individuals presenting with alcoholic 
hepatitis have underlying fibrosis or cirrhosis, presenting as an acute-on-chronic 
condition.10, 11 Approximately 10% to 35% of heavy drinkers will develop alcohol 
hepatitis and some degree of fibrosis.7, 13 There is a high short-term mortality associated 
with alcoholic hepatitis, averaging between 30 – 50% at 3-months.11 
Liver fibrosis occurs as stellate cells in the liver lose vitamin A content and begin 
synthesizing and depositing collagen and other extracellular matrix proteins in a 
response to chronic liver injury.10 Hepatocyte death occurs with ongoing inflammation to 
the liver, and these cells are replaced by scar tissue.10 When the liver has some 
scarring, this is referred to as fibrosis. As accumulation of scar tissue in the liver 
increases and takes over the majority of the liver, this is referred to as cirrhosis and 
develops in 10% to 15% of heavy drinkers.7, 13 It is estimated that between 80% and 
90% of hepatocytes must be damaged before impairment of physiological function 
occurs, and some of the outward expressions of the disease may manifest.14 Cirrhosis 
causes a host of very serious clinical features including hepatic encephalopathy, portal 
hypertension, ascites, malnutrition, jaundice and esophageal varices.10, 14 Diagnosis of 
cirrhosis often occurs when individuals experience jaundice or other symptoms in the 
setting of an episode of alcoholic hepatitis.11 Liver decompensation occurs in the setting 
of severe complications resulting from cirrhosis, including ascites or hepatic 
encephalopathy.14 Hepatocellular carcinoma incidence is on the rise, which occurs in 
about 1% to 2% of individuals with liver cirrhosis caused by alcohol.15  
There is a general dose-response relationship between the amount of alcohol 
consumed and risk of developing ALD, however amount and type of alcohol consumed, 
drinking frequency, drinking patterns and other known risk factors also may impact risk 
of disease development.11 Other risk factors for developing ALD besides heavy alcohol 
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consumption include obesity, cigarette smoking, female sex and inherited propensity.10 
Genetic factors may include variations in genes for PNPLA3, certain inflammatory 
mediators or enzymes that metabolize alcohol.10 Heavy drinking with other conditions 
including HIV, hepatitis B or C, nonalcoholic fatty liver disease and hemochromatosis 
also increases risk for development of ALD and speeds progression of preexisting 
ALD.10 Interestingly, high coffee consumption (greater than four cups per day) appears 
to serve as a protective factor in multiple outcomes associated with ALD.16 For 
individuals with known ALD, continued alcohol consumption is the most significant risk 
factor and poses the highest risk for disease progression.10  
 
Classifying alcohol use and relationship to risk for alcoholic liver disease 
Alcohol consumption is most commonly measured by of grams of alcohol, 
number of drinks or standard drink equivalents (14 grams of alcohol in the US), 
consumed over various defined timeframes pending the rationale for inquiry.11 There 
are multiple guidelines used for defining alcohol use and drinking levels depending on 
the rationale and organization. Commonly used classifications are found in the 2015-
2020 US Dietary Guidelines, which incorporate standards from the National Institute on 
Alcohol Abuse and Alcoholism (NIAAA).2, 17 See Table 1 for a summary of these 
classifications. 
 
Table 1. Summary of drinking levels defined in 2015 – 2020 US Dietary Guidelines 
 
Drinking level Definition for women Definition for men 
Moderate drinking Up to 1 drink/day Up to 2 drinks/day 
Heavy drinking 8 or more drinks/week 15 or more drinks/week 
Binge drinking 4 drinks/2-hour time 
frame 
5 drinks/2-hour time 
frame 
Note: One drink is equivalent to 14 grams of pure alcohol in the US 
Table produced by the author using information from US Department of Health and 
Human Services and US Department of Agriculture 17 
 
Some people who engage in consistent drinking patterns beyond moderate 
drinking may meet criteria for alcohol use disorder. Alcohol use disorder is defined in 
the Diagnostic and Statistical Manuel of Mental Disorders V (DSM-V), and includes 
eleven potential effects of alcohol use including biological impacts, behavioral impacts, 
social impacts and medical harm.18 A minimum of two criteria must be met for an 
individual to be diagnosed with alcohol use disorder, and severity depends on the 
number of criteria a person meets.18  
Moderate drinkers do not have increased risk of liver injury compared to people 
who completely abstain from drinking.11 Beyond moderate drinking, establishing a 
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threshold for alcohol intake upon which risk for ALD increases is difficult due to the 
multiple risk factors contributing to overall risk for disease, as well as other factors 
including type of alcohol consumed and pattern of drinking.19 Bellentani et al proposed 
30 grams of alcohol per day in both men and women as the minimum amount 
associated with an increased risk for ALD based on their work in northern Italy.19 
Establishing timeframes of heavy alcohol use for increased risk of developing ALD can 
also be challenging; some reports suggest increased risk does not occur below daily 
drinking of 30 grams of alcohol for ten years.12 Binge drinking is a topic of great interest 
to liver disease specialists as the prevalence of binge drinking especially among young 
people appears to be on the rise.11 Currently, there is limited research concerning 
impact of this pattern of drinking in respect to liver disease development or 
progression,11 however there appears to be increased risk for severe liver disease 
development associated with daily drinking compared to episodic or binge drinking.20 
The highest prevalence of cirrhosis in the Bellentani study was among individuals who 
drank greater than 120 grams per day (about 8 to 9 drinks per day).19  
 
Diagnostic methods 
The challenge of early diagnosis of ALD is multifactorial, and is exasperated by 
the common course of the disease initially presenting with minimal or no symptoms in 
patients with early stages of the disease.9 Outward expressions of the disease, report of 
heavy alcohol use or clinical biomarkers associated with ALD can provoke clinicians to 
pursue further diagnostic measures.9, 15 Abnormal laboratory tests including 𝛾-
glutamyltransferase, aspartate amino transferase, alkaline phosphatase and mean 
corpuscular volume of red blood cells may indicate early ALD.9, 14 Abnormal bilirubin, 
international normalized ratio, albumin and platelet count may be indicative of a more 
advanced stage of alcohol liver disease.9, 15 Imaging technologies including magnetic 
resonance imaging, computed tomography and ultrasonography are useful in 
diagnosing ALD, including early stages of steatosis.9 Fibroscan, also known as transient 
elastography, was approved for use in the United States in 2013 and detects degree of 
liver fibrosis by measuring shear wave velocity to measure liver stiffness.9 There are 
certain contraindications to its usage, including morbid obesity, presence of ascites and 
high amounts of chest wall fat. However, this diagnostic technique holds potential due to 
its noninvasiveness, low cost, instant results and minimal risks associated with the 
procedure.21 Other newer imaging technologies being studied for use in early diagnosis 
of liver disease include real-time 2D shear wave elastography, in which incorporates 
traditional ultrasound imaging with real-time shear wave visualization to measure liver 
stiffness.22 Liver biopsies have some limitations including its invasive nature, high cost, 




Factors driving lack of early detection and referral 
Lack of widespread use of an effective screening tool  
As outlined above, ALD generally presents asymptomatically in early stages, 
often times leading to a diagnosis which occurs when complications associated with 
decompensation occur.9, 23 According to the NIAAA, in 2015 over 25% of people in the 
US reported engaging in binge drinking in the past month, 7% reported engaging in 
heavy drinking in the past month and an estimated 6% of people met criteria for alcohol 
use disorder.2 Of all people who have alcohol use disorders (about 16.6 million people) 
only about 10% to 20% will ever develop cirrhosis.23 Screening for ALD that is both cost 
effective and reliable is thus challenging given this small proportion of disease 
prevalence within a large group of individuals.23 Screening tools for identifying 
individuals who engage in heavy drinking are routinely used in various healthcare 
settings (discussion below), however there are currently no widespread screening 
methods being routinely used to assess individual susceptibility to developing ALD or 
presence of fibrosis within the group of people who engage in heavy drinking.10, 23 
Several of the noninvasive imaging technologies discussed above show promise for 
identifying individuals with significant fibrosis, the precursor to cirrhosis, however a 
widespread and systematic approach has yet to be adopted and implemented.22  
 
Alcohol use underreporting 
 Much of the research on self-reported alcohol use involves population surveys. 
This data is gathered to generate estimates of consumption on the population-level, 
which is used for monitoring trends over time, identifying similarities and differences of 
consumption patterns between sub-groups within the population and informing public 
policy. Studies consistently demonstrate underestimation of alcohol consumption of up 
to 50%, when researchers compare survey responses to sales and/or tax data.24, 25, 26 
Contributing factors to underestimation in these population surveys on alcohol use 
include response bias, survey undercoverage and inaccurate estimates of alcohol 
intake.26  
There may be several factors driving inaccuracy of estimating alcohol 
consumption. One study suggested that survey questions that asked respondents for in-
depth and detailed measures concerning their alcohol intake from the previous day 
allowed for significantly greater coverage than survey questions that were aimed at 
capturing alcohol intake over the previous year,27 and multiple studies have 
demonstrated that utilizing detailed questions on alcohol consumption produce higher 
consumption results.28 Utilization of standard alcohol drinks or units may also contribute 
to inaccuracy of self-reported alcohol intake. Multiple studies have demonstrated that 
people consistently pour larger drinks than what is considered to be the standard 
alcohol unit.5, 29, 30 Stockwell (2004) accredited greater coverage in alcohol consumption 
to the study design feature in which respondents had to pick the unit of alcohol rather 
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than estimating number of drinks based on a standard unit, which is the widespread 
methodology for estimating alcohol intake in surveys and face-to-face interviews.27 
 Data collection on alcohol consumption at the population level is beneficial in 
regards to ALD in that it can allow for trends to be monitored, to identify high risk groups 
and to inform alcohol related policy and program development. Individuals with liver 
cirrhosis that derives from nonalcoholic fatty liver disease or viral hepatitis may present 
with outward expressions of known risk factors, such as obesity or perhaps a previous 
hepatitis diagnosis.31 Due to the often silent course of early stages of liver cirrhosis, the 
importance of identifying heavy drinking behavior as a risk factor for developing liver 
cirrhosis, is critical as there may be no obvious presenting risk factors as is the case 
with other etiologies of liver cirrhosis. There are hundreds of screening tools utilized in a 
spectrum of healthcare facilities to identify heavy drinking behavior, with a variety of 
primary target audiences and administration methods, all with varying degrees of 
reliability. The most common screening tools in the United States include CAGE and 
AUDIT, due to their widespread applicability in a variety of healthcare settings and array 
of target populations.32 The CAGE questionnaire includes four yes/no questions, 
including: 1) Have you ever felt that you ought to Cut down on your drinking? 2) Have 
people Annoyed you by criticizing your drinking? 3) Have you ever felt bad or Guilty 
about your drinking? 4) Have you ever had a drink first thing in the morning to steady 
your nerves or get ride of a hangover (Eye-opener)? Scores range from 0 to 4, and 
score cutoff for problem drinking is greater than or equal to 1 or 2 depending on the 
institution using the tool.32 Although praised for being easily administered and having 
adequate validity for detecting problem drinking in medical, surgical and psychiatric 
inpatients and ambulatory medical patients, according to a recent review it does not 
perform well for identifying heavy drinking, or in specific sub-populations including white 
women, prenatal women and college students.33  
The AUDIT (alcohol use disorders identification test) questionnaire includes ten 
questions inquiring about amount of alcohol consumed, drinking behaviors (such as 
drinking in the morning or loss of memory related to drinking), and social consequences 
of drinking (such as feelings of remorse after drinking).32 The AUDIT performs better 
than the CAGE questionnaire for identifying various forms of problem drinking, however 
takes longer to administer and score.33, 34 Despite being generally accepted for use in a 
variety of settings with various populations,35 the AUDIT does utilize standard drink 
equivalents to estimate amount of alcohol consumed, which raises concern for accuracy 
of respondent estimation, even without incorporating potential underreporting due to 
stigma associated with heavy alcohol use. This feature of the AUDIT questionnaire, 
along with other alcohol screening tools, highlights the need for an assortment of 
strategies to identify people who are at risk for developing complications related to 
heavy alcohol use, including ALD.  
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Measuring and determining alcohol consumption among populations and 
individuals is no easy task, however is vital in improving the ability to detect liver 
disease at a stage in which interventions still have the potential to halt disease 
progression. Due to the often silent presentation of ALD in early stages, it is imperative 
that heavy alcohol users be identified so that further assessment for presence of liver 
disease be evaluated and monitored prior to the occurrence of liver decompensation. 
 
Lack of training of healthcare professionals  
 Developing screening tools that aim to identify individuals with problematic 
drinking is only one piece of the complex issue of early detection of ALD. Whether or 
not these tools are actually being implemented in practice, how well, and what providers 
do with the information gathered from these screening tools, are other critical factors in 
this complex issue. The CASA National Survey of Primary Care Physicians and Patients 
on Substance Abuse is widely regarded as the most comprehensive survey on the 
interactions between health care providers and patients with alcohol and substance 
abuse.36 The findings from the survey highlight several worrying aspects for how heavy 
alcohol use is addressed in practice. Of the physicians surveyed, only 30% carefully 
screened for substance abuse in their practice.36 To have met criteria for careful 
screening, physicians had to implement three of the following measures into their 
practice: administer some kind of substance abuse screening tool, include questions on 
the health history form pertaining to alcohol use, almost always ask patients about 
substance abuse when problematic use is suspected or almost always discuss 
substance use with pregnant patients.36 While the development of validated and 
effective screening tools is commendable, if they are not being used routinely in 
practice, the effect is lost. 
The CASA survey also revealed that less than 20% of physicians considered 
themselves ‘very prepared’ to identify alcohol abuse and diagnose alcoholism.36 One of 
the potential factors contributing to this lack of preparedness is the lack of training 
physicians receive in alcohol and substance abuse. A survey conducted by the Liaison 
Committee for Medical Education (LCME) revealed that of the 125 US accredited 
medical schools, only 12 had a separate required course on the subject and only 45 
offered an optional elective course on the topic.37 Interestingly the LCME, which is 
responsible for accrediting all US medical schools, only requires that medical schools 
include “behavioral subjects” in curriculum, without specific requirements related to 
alcohol or substance abuse. As Ram and colleagues point out, key words such as 
“alcohol,’ ‘substance’ and ‘addiction’ are completely absent in the publication of LCME 
2014 standards, “reflecting the lack of congruence between current medical school 
curricular requirements and public health needs.” 37 Other studies have analyzed the 
amount of time dedicated to substance use in residency programs across the country. 
One such study examining substance abuse found that the percentage of residency 
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programs with required training on the topic varied, ranging from 32% (pediatrics) to 
95% (psychiatry), with 57% of all programs combined with required training on 
substance abuse.38  
This lack of training on alcohol and substance abuse has multiple effects that may 
exacerbate physicians’ feelings of unpreparedness. Of physicians surveyed, 40% 
reported finding talking about alcohol abuse difficult and uncomfortable.36 Less than 4% 
of physicians surveyed believed that treatment for alcoholism was effective and over 
half of physicians cited belief that patients are dishonest about their substance use as 
rationale for not attempting to discuss substance abuse with patients.36 
A noteworthy finding from the CASA survey was that 85% of patients did admit to 
being dishonest about their substance use to their primary care physicians.36 It is 
important to consider why patients do not feel comfortable talking about their substance 
use with providers. Some of the reasons cited for why patients don’t feel comfortable 
speaking with their primary care physician were shame (84%), lack of empathy from the 
physician (37%), fear that the physician will tell their families (54%) and not ready to 
stop misusing alcohol or drugs (54%).36 Of the patients surveyed who did talk to their 
physician about their substance abuse, over half reported that they (not the physician) 
had initiated the conversation regarding substance use.36 This vicious cycle of patients 
and providers not feeling comfortable to talk about alcohol use with one another may be 
a driving force in the under detection of heavy alcohol use.  
Due to the number of health risks associated with heavy alcohol use including ALD, 
identification of individuals who are heavy users is essential.37 All physicians, regardless 
of area of practice or specialty, will come across alcohol and other substance abuse, 
and the various associated health ramifications.37 Substance abuse and addiction 
specialists do have a distinct role in treating individuals in overcoming alcohol and 
substance abuse issues, however every physician needs to be competent in screening, 
diagnosing, managing associated health conditions and making referrals when 
appropriate due to the widespread nature of alcohol and substance abuse in the 
country.37 
 
Discrepancies in alcohol related research and resources available relative to disease 
burden 
To explore disparities in early detection and treatment for various etiologies of 
liver disease, a recent systematic review examined data on the research attention given 
to various types of liver disease.39 The authors quantified research attention for each 
type of liver disease by examining five categories including major scientific liver 
meetings, drugs in development, research opportunities, clinical trials and publications 
(see Figure 2). Disease burden was determined using seven different parameters under 
four main categories: hospitalization discharges and costs, mortality, cause of fibrosis 
and cirrhosis and cause of liver transplantation in the US and European Union (see 
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Figure 3). The researchers then calculated a mean attention-to-burden score based on 
this data and found ALD had a 10-fold under-attention score while viral hepatitis had a 5 
to 7-fold over-attention score. The researchers hypothesized that this disparity has in 
part fueled the lack of advancement for early detection, management and treatment for 
ALD.39 The authors contribute this discrepancy to a host of complex issues, including 
social stigma surrounding alcoholism and poor awareness of the disease.39 
 
Figure 2. Estimation of mean research attention to four etiologies of liver disease 
 












Figure 3. Estimation of mean disease burden of four etiologies of liver disease 
 
 
Reproduced with permission from Ndugga et al 39 
 
Also alarming is the upcoming trajectory for available funding for alcohol related 
research. In the United States, the National Institute of Alcohol Abuse and Alcoholism 
(NIAAA) is one of the 27 institutes that encompass the National Institutes of Health 
(NIH) of the US Department of Health and Human Services. The NIAAA is considered 
the lead agency in the US for alcohol related research. Funding for the NIAAA comes 
from the US government after congressional approval of the Presidential budget 
proposal.40 This year, funds allocated for the NIAAA is approximately 361 million dollars, 
almost a quarter less than the 2017 fiscal year funding of approximately 467 million.40 
 
Case example illustrating some key mediators in lack of early detection and referral of 
ALD 
An example from the author’s experience is a case based on an actual 
hospitalized patient and depict some of the interconnected and interacting factors that 
drive the lack of early detection and referral of ALD discussed above. Identifying details 
have been changed to protect the individual’s identity.  
Case #1 was a 39-year old African-American female admitted to the burn unit 
from an outside hospital for concern over a potential inhalation injury after accidentally 
swallowing a crack rock while smoking using a pipe. Pertinent medical history included 
tobacco use, obesity, hypertension, substance use disorder and alcohol use disorder. 
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Upon admit, the patient admitted to drinking about two bottles of wine per day for over 
fifteen years. Upon evaluation, it was revealed that there was no evidence of inhalation 
injury. Other relevant findings in the standard initial work-up revealed abnormal 
aspartate amino transferase, total bilirubin, direct bilirubin and 𝛾-glutamyltransferase. In 
the morning rounds, it was decided among the critical care team that the patient would 
be discharged from the hospital that morning without further evaluation. Reasons cited 
for immediate discharge included belief that she is “just going to go back to drinking,” 
and urgency in timeliness was expressed due to not wanting the patient to begin alcohol 
withdrawal. A voucher for cab fare was issued and the patient was discharged without 
further evaluation or referrals, within eight hours of being admitted. 
This case example depicts a scenario in the patient was admitted to the hospital 
and heavy drinking was identified, however was not the primary reason for admission. 
Multiple risk factors for ALD were present including heavy drinking, female sex, obesity 
and cigarette smoking, however further assessment of liver function and exploration of 
potential fibrosis was not conducted. This case illustrates an all too common occurrence 
indicative of many interacting and complex factors discussed above, including 
insufficient training of healthcare professionals, lack of standardized screening 
parameters for ALD and lack of widespread use of noninvasive diagnostic tools.  
 
Role of the dietitian 
Relationship between alcoholic liver disease and nutrition status 
Individuals who abuse alcohol chronically often present with varying degrees of 
malnutrition due to replacement of nutrients with alcohol and interference with 
absorption and metabolism of nutrients that are consumed due to alcohol’s 
physiological impact in the body.41 Due do the high prevalence of malnutrition among 
alcoholics, many clinicians historically believed that malnutrition was responsible for 
ALD.41 However, human and animal studies have since demonstrated that liver injury 
and ALD can develop even in well-nourished individuals, leading to a more 
comprehensive and balanced understanding of the pathogenesis of ALD.41  
The development of malnutrition as a complication of ALD is more prevalent than 
in other forms of liver disease unrelated to alcohol.42 Prevalence estimates include 
approximately 20% in compensated ALD and 80% in decompensated ALD.42 It is 
commonly recognized that the development of malnutrition in ALD is multifactorial, 
involving impaired macronutrient and micronutrient metabolism related to altered liver 
function, impacts of alcohol use, maldigestion, malabsorption, gastrointestinal 
disturbances and consequences of typical complications impacting oral intake, such as 
nausea, vomiting and early satiety.14 Consideration of the numerous roles the liver plays 
in metabolism of proteins, carbohydrates and fats makes apparent why malnutrition 
develops as a complication of the disease. The liver is a major site for plasma protein 
synthesis, nonessential amino acid synthesis and other critical proteins such as those 
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needed for blood clotting.7, 14 Carbohydrate metabolism include storage of glucose as 
glycogen, producing glucose from glycogen when needed for energy, conversion of 
galactose and fructose into glucose and is the site of gluconeogenesis, which produces 
glucose from alternative substrates when necessary.7 Beta oxidation of fatty acids and 
production of ketones occurs in the liver, and is also a site for the synthesis and 
hydrolysis of triglycerides, phospholipids and cholesterol.7 Other critical roles of the liver 
include storage of all fat soluble vitamins and several micronutrients, conversion of 
several vitamins to their active form, formation and excretion of bile, conversion of 
ammonia to urea, metabolism of steroid hormones and detoxification of substances like 
drugs and alcohol.7  
The most well-known and extensive studies on malnutrition as a complication of 
ALD come from the US Department of Veterans Affairs (VA) Cooperative Studies 
Program.14 One landmark study from the VA Studies Program found that nearly 100% 
of patients with alcohol hepatitis had some degree of malnutrition, and that over half of 
the participants with alcoholism without underlying liver disease also presented with 
some degree of malnutrition.43 A follow-up study from the VA Cooperative Studies 
Program demonstrated similar findings, with 100% of study participants with 
decompensated ALD displaying some degree of malnutrition.44 In this later study, 
researchers also monitored patient caloric intake (patients ate ad libitum) and stratified 
patients into groups based on calories consumed. A highly significant relationship (p = 
0.001) was found between caloric intake and mortality rate, with the highest mortality 
among those who ate less than 1000 calories per day and virtually no mortality among 
those who ate greater than 3000 calories per day. See Figure 4. 
  
Figure 4. Six-month mortality associated with caloric intake in 245 patients 
 
Reproduced with permission from Mendenhall et al 44 
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Further stratification of patients based on severity of malnutrition revealed a 
significant association between malnutrition and development of severe complications 
and mortality rate.44, 45 It is important to note however, that these findings did not denote 
a causal relationship between caloric intake or nutrition status and prognosis, but rather 
reflected the interrelationship between disease severity, nutrition status, caloric intake 
and disease progression.14 These findings, as well as numerous other studies on the 
subject, did however suggest that malnutrition is a complication from ALD and that 
malnutrition is associated with worse clinical outcomes for the patient.14 
These VA cooperative studies on nutrition status and ALD have helped to fuel 
further research exploring effects of nutrition support among this patient population. 
Although caloric intake was found to be significantly associated with mortality in these 
studies, it is possible that disease severity was impacting patients’ ability to eat, and that 
those with lower caloric intake and higher mortality were just sicker patients with worse 
baseline prognosis.14 There have been a number of randomized trials exploring various 
routes of nutrition support (oral supplements, enteral nutrition, parenteral nutrition) for 
patients with cirrhosis, with varying results. According to a 2012 Cochrane systematic 
review examining the various modalities of nutrient provision to this patient population, 
there is not sufficient evidence to warrant establishing recommendations for any routine 
provision of nutrition support.46 There were some significant findings though, including 
potential benefits of parenteral nutrition in reducing serum bilirubin, potential benefits of 
enteral nutrition improving nitrogen balance and decreasing complications 
postoperatively and potential benefits of oral supplements decreasing incidence of 
ascites, infection and hepatic encephalopathy.46 A recent systematic review and meta-
analysis found also found that no conclusions could be made regarding type of nutrition 
modality or duration of therapy, however the authors did find that the body of literature 
included in their review suggested that overall, nutrition therapy may decrease mortality 
in patients with alcoholic hepatitis or cirrhosis.47  
There have been some recent promising studies supporting the potential benefit 
of nutrition support among this patient population. In 2016, Moreno et al published a 
report on their randomized trial examining enteral nutrition compared to conventional 
oral nutrition among patients with alcoholic hepatitis, with the primary outcome 
measurement being mortality at 6 months.48 Although no significant difference was 
found between exposure groups, one very notable finding arose. Patients that received 
less than 21.5 kcal/kg per day had significantly higher mortality than those who received 
greater than this amount, regardless of whether nutrition was in conventional or enteral 
form.48 The authors deducted that clinical outcomes were not a consequence of liver 
disease severity because baseline characteristics based on prognostic scoring systems 
were comparable between patients who fell below and above this caloric threshold.48 
The authors stress the importance of patients achieving sufficient energy intake to 
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prevent falling below this 21.5 kcal/kg threshold, which was associated with significantly 
higher mortality.48  
Other studies have produced similar findings suggestive of malnutrition as an 
independent predictor of developing severe complications associated with cirrhosis and 
with higher mortality, as well as the potential benefits of nutrition support. One 
randomized trial examined effects of enteral nutrition compared to standard 
corticosteroid treatment for alcoholic hepatitis.49 There was no significant difference in 
one-month mortality outcomes, however in the one-year mortality outcomes, patients 
receiving enteral nutrition had significantly lower mortality than those receiving the 
steroid.49 Some studies have demonstrated the potential benefits of promoting oral 
intake, which may be of particular value in outpatient settings. Hirsch et al demonstrated 
that patients receiving oral enteral supplementation had fewer hospitalizations 
compared to the control group.50 Another study demonstrated the benefit of a nighttime 
snack before bedtime in maintaining body protein, as patients’ depleted glycogen stores 
causes gluconeogenesis and body muscle breakdown to occur more rapidly.51 
It is worth noting several other factors that complicate the issue of optimizing 
nutrition support for people with ALD. As mentioned previously, the cause of 
malnutrition is often multifactorial, which may include multiple causes for poor oral 
intake (nausea, early satiety, taste changes, abdominal pain, loss of appetite), 
malabsorption, increased energy expenditure and altered mechanisms for fuel 
consumption.14, 52 In regards to determining the best nutrition modality, another finding 
from the Moreno study as well as others on the topic, is the common occurrence of 
patients with ALD prematurely withdrawing feeding tubes.48, 49, 53 This causes 
interruption to the provision of nutrients as planned. Also, it is widely recognized that 
parenteral nutrition should be used only as a last resort among this patient population 
due to increased risk for infection and further liver injury, among other risks.14 These are 
all important factors to be considered when determining how best to optimize a patients’ 
nutrition status and to support the patient in meeting nutrient needs. ASPEN currently 
recommends 35 – 40 kilocalories per kilogram of patients’ weight and 1.0 – 1.5 grams of 
protein per kilogram of patients’ weight as general nutrition guidelines for this patient 
population.14 
Given the current trend of lack of early referral in patients with ALD, and the 
common occurrence of patients presenting for care with decompensated liver disease, 
the dietitian plays an important role in supporting the patient to optimize nutrition status 
to attenuate disease progression and severity. Full discussion of nutrition assessment 
and potential interventions is not in the scope of this report. Due to the wide variability in 
disease presentation and progression, as well as the individual’s ability and wishes to 
tolerate various nutrition modalities, providing nutrition support to people with ALD must 
be tailored specifically for the individual.14 Identifying and diagnosing malnutrition 
appropriately is a critical and needed first step to link individuals with nutrition support 
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that may improve their quality of life, decrease risk for developing complications and 
even improve prognosis.  
 
Identifying and diagnosing malnutrition  
In order to provide nutrition therapy to those with impaired nutrition status, a need 
for nutrition support has to be established. One of the challenges in establishing need 
for nutrition support is the difficulty in nutritional assessments among this patient 
population.52 Common complications of decompensated cirrhosis include edema and 
ascites; this fluid accumulation can make assessment of weight loss challenging.14, 52 
Bioelectrical impedance is also affected by the presence of ascites or edema.7 Some 
anthropometric measurements used to assess nutrition status, such as mid-arm 
circumference or triceps skinfold-thickness have limitations including high variability 
between those taking measurements.52 Hepatorenal syndrome associated with ALD can 
impact other nutrition assessment parameters including creatinine-height index and 
nitrogen balance studies.7  
These challenges in assessing nutrition status contribute to the frequently 
underestimated and undetected presence of malnutrition among individuals with 
ALD.54,55 ASPEN currently recommends a comprehensive nutrition assessment utilizing 
assessment criteria such as the Subjective Global Assessment (SGA), which 
incorporates multiple variables including weight change, dietary intake change, 
gastrointestinal symptoms, functional capacity and nutrition focused physical findings, to 
provide a more accurate evaluation of nutrition status.14 New tools such as the Royal 
Free Hospital-Nutritional Prioritizing Tool, which evaluates risk for malnutrition rather 
than presence of malnutrition, show much promise for preventing and addressing 
malnutrition in early stages.56  
 
Conclusion 
The lack of early detection and referral of alcoholic liver disease is driven by a 
number of factors discussed in this report, including lack of widespread use of an 
effective screening tool, alcohol use underreporting, lack of training of healthcare 
professionals and discrepancies in alcohol related research and resources available 
relative to disease burden. The implication of detection and referral after 
decompensation has occurred is grave due to the irreversible nature of liver cirrhosis 
and the higher mortality rates associated with complications relevant to 
decompensation.12 Given the current trend of lack of early referral, this highlights the 
need to provide patients with advanced alcoholic liver disease the support and care to 
decrease risk for complications and mortality, and improve quality of life. Nutrition 
support has been shown to have this potential and should be considered in all patients 
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